Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, patients with androgenetic alopecia who received type A botulinum toxin treatment showed increased follicle width and length at the vertex and left frontal area over three months, but no significant changes in follicle or hair count compared to the control group.

This study found significant differences in serum lipoprotein (a) and triglyceride levels between men with androgenetic alopecia and those with normal hair, suggesting a need for dermatologists to monitor lipid profiles in these patients.

Men with a certain type of hair loss (AGA) have higher bad cholesterol and lower good cholesterol levels, making them more likely to get heart disease.

This study found that men with vertex type androgenetic alopecia had higher triglyceride levels and lower HDL cholesterol levels compared to those with normal hair, suggesting it may be a marker of hyperlipidemia.

In this study, the vertex type of male pattern baldness was associated with increased cardiovascular risk factors, suggesting it may serve as a marker for cardiovascular evaluation in men.

This study found that the prevalence of androgenetic alopecia in Chinese men was lower than in Caucasian men, similar to Korean men, and most commonly presented as type III vertex.

In this study, platelet-rich plasma injections improved hair density by 19.17% in men with androgenetic alopecia over six months, although results varied by alopecia pattern.

A man developed hair loss from testosterone treatment but improved with additional medication.

In this study, young Thai men with androgenetic alopecia reported poorer quality of life compared to older men, as indicated by higher DLQI scores.

This study found that increased expression of type 2 TGF-β and type II receptor was observed in the bald vertex area of hair follicles from androgenetic alopecia patients, suggesting a role in catagen induction.

This review explores the causes and diagnostic methods for androgenetic alopecia but reports no new clinical results, underlining the importance of developing new treatments.

Atypical male hair loss may not respond to usual treatments.

This study found that in androgenetic alopecia patients, there is enhanced expression of type 2 TGF-β and type II receptors in hair follicles, suggesting a link to hair growth cycle changes.

This study found that SDR5A1 gene expression was similar between hirsute women, normal women, and men, suggesting it may not explain differences in hair growth among these groups.

In this case report, the researchers emphasize the importance of regular prostate exams and PSA tests for diabetic men, including those who are hypogonadal, because prostate cancer development is linked to intraprostatic dihydrotestosterone levels, not serum testosterone levels.

This study found that men with vertex baldness had higher serum dihydrotestosterone levels compared to those with frontal baldness, suggesting different hormonal profiles between these two groups in androgenetic alopecia.

In this study of patients with androgenetic alopecia, botulinum toxin type A was found to significantly increase hair counts and improve hair density and coverage, with enhanced results observed when combined with oral finasteride, revealing a safe and effective treatment approach without adverse effects.

This study found that Plumbago zeylanica extract and its component plumbagin may help prevent androgenetic alopecia by promoting dermal papilla cell growth and reducing SRD5A2 expression.

This study found that topical minoxidil 5% foam was effective in promoting hair growth in both the frontal and vertex scalp for men with androgenetic alopecia.

This study developed a new semiquantitative grading scale for frontal and vertex androgenetic alopecia, which was found to be more sensitive and objective than existing classifications.

This study found that a topical solution combining 0.25% finasteride with 3% minoxidil significantly improved hair growth, as measured by hair density, diameter, and global assessment, in men with androgenetic alopecia, compared to 3% minoxidil alone, over 24 weeks without systemic adverse effects reported.

This study found that finasteride 1 mg improved hair growth in 85.7% of Korean men with androgenetic alopecia over five years, with varying effectiveness depending on the type of hair loss.

This study found that early-onset androgenetic alopecia, especially with a vertex pattern, may be an independent risk factor for cardiovascular disease and metabolic syndrome in men.

Balding men have harder scalps.

This study found that patients with severe vertex pattern androgenetic alopecia had significantly higher carotid intima-media thickness, suggesting an increased risk of subclinical atherosclerosis compared to other alopecia patterns and healthy controls.

In this study, researchers found that the existing Norwood and Hamilton classifications for androgenetic alopecia in Indian males had significant limitations, with 18% of cases not fitting into existing pattern categories.

This study suggests the average age of onset for androgenic alopecia may be decreasing, but a longer-term study is needed to confirm this observation.

This study found that androgenic alopecia was associated with a decreased risk of testicular germ cell tumors but a potential increased risk of high-grade prostate cancer.

This study found that the prevalence of androgenetic alopecia in Chinese men and women was lower than in Caucasians and similar to that in Koreans.

In this study, the researchers did not confirm previously reported links between AGA and smoking or benign prostatic hypertrophy, but found potential associations with alcohol consumption and lean body mass at age 21 that merit further investigation.